[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357375-105":59,"doc-detail-357375-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dose-dense-adjuvant-chemotherapy-in-her2-low-breast-cancer-an-exploratory-analysis-of-the-gim2-trial","Dose-dense adjuvant chemotherapy in HER2-low breast cancer - An exploratory analysis of the GIM2 trial","","Dose-dense (DD) adjuvant chemotherapy is a standard option for patients with high-risk node-positive early-stage HER2-negative breast cancer. This exploratory analysis of the GIM2 trial evaluates DD chemotherapy efficacy by HER2 immunohistochemistry (IHC) classification. Among 1243 eligible participants, tumors were categorized as HER2-zero, HER2-low, or HER2-negative with unknown IHC score. At median 14.9-year follow-up, no interaction with HER2 status was detected for iDFS or OS, and benefits of DD were observed across subgroups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dose-dense-adjuvant-chemotherapy-in-her2-low-breast-cancer-an-exploratory-analysis-of-the-gim2-trial/357375/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dose-dense-adjuvant-chemotherapy-in-her2-low-breast-cancer-an-exploratory-analysis-of-the-gim2-trial/357375.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of the GIM2 exploratory analysis?","Question",{"text":112,"@type":113},"To investigate the efficacy of dose-dense adjuvant chemotherapy in HER2-negative breast cancer, stratified by HER2 immunohistochemistry (IHC) score categories.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were tumors classified based on HER2 status in the study?",{"text":117,"@type":113},"HER2 score 0 tumors were labeled HER2-zero; tumors with HER2 score 1+ or 2+ without ISH amplification were classified as HER2-low; cases with unknown IHC score were grouped separately.",{"name":119,"@type":110,"acceptedAnswer":120},"Did the study find that DD chemotherapy benefited patients regardless of HER2 status?",{"text":121,"@type":113},"Yes. No interaction between treatment effect and HER2 status was observed for invasive disease-free survival or overall survival, and efficacy signals were reported across HER2-zero and HER2-low groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357375,1790190388,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","The Breast 88 (2026) 104848  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial\u003Cbr>Chiara Molinelli a,b , Virginia Delucchic, Eva Blondeaux c, Luca Bonic, Francesca Poggio b, Davide Soldatob, Ludovica Antonja,b, Grazia Arpinod, Cecilia Nistic`o e, Alessandra Fabif, Michelino De Laurentiis g, Giuseppe Buono g, Fabio Puglisih,i, Guilherme Nader-Martaj,k,l, Alessandra Fozzam, Francesca Pitton , Federica Boncore c, Barbara Cardinalib,\u003Cbr>Piero Fregatti o,p, Matteo Lambertini a,q, Lucia Del Mastroa,b,* \u003Cbr>a Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy b Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy c U. O. Epidemiologia Clinica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy\u003Cbr>d Department of Clinical Medicine and Surgery, University of Naples \"Federico II\", Naples, Italy e Medical Oncology Unit, ASL Frosinone, Frosinone, Italy\u003Cbr>f Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy g Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\", Naples, Italy h Department of Medicine, University of Udine, Udine, Italy\u003Cbr>i Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano,(PN), Italy\u003Cbr>j Universit´e Libre de Bruxelles (U.L.B), Hˆopital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium k Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA\u003Cbr>l Harvard Medical School, Boston, MA, USA\u003Cbr>m Radiation Oncology Department, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy n Pathology Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy\u003Cbr>o Department of Surgery, U.O. Senologia Chirurgica, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy\u003Cbr>p Department of Surgical Sciences and Integrated Diagnostic (DISC), School of Medicine, University of Genoa, Genoa, 16132, Italy q Academic Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genova, Italy | |\n| --- | --- |\n\nA R T I C L E I N F O  \nKeywords:  \nBreast cancer  \nDose-dense chemotherapy HER2-Low  \nA B S T R A C T  \nBackground: Dose-dense (DD) adjuvant chemotherapy represents a standard treatment for patients with high-risk node-positive early-stage HER2-negative breast cancer (BC). In this exploratory analysis of the GIM2 trial, we investigated the efficacy of DD chemotherapy among patients with HER2-negative BC according to HER2 immunohistochemistry (IHC) score.  \nMethods: Patients with node-positive early BC were randomized to receive either DD or standard schedule anthracycline- and taxane-based chemotherapy. HER2 status was assessed locally. Tumours with HER2 score 0 were classified as HER2-zero, those with a HER2 score 1+ or 2+ without ISH amplification as HER2-low. Tumours classified as HER2-negative with unknown IHC score were considered as a separate subgroup.  \nResults: Overall, 1243 subjects were eligible for this analysis, with 475 (38.2%) tumours classified as HER2-zero, 446 (35.9%) as HER2-low and 322 (25.9%) as HER2-negative with unknown IHC score. At a median follow-up of 14.9 years (IQR 8.4-16.2), no interaction was observed between treatment effect and HER2 status in invasive disease-free survival (iDFS) (p for interaction = 0.42) nor in overall survival (OS) (p for interaction = 0.34). Efficacy of DD chemotherapy was observed regardless of HER2 status: among patients with HER2-zero tumours, adjusted hazard ratio (aHR) for iDFS was 0.62 (95% confidence interval [CI] 0.45-0.85) and for OS was 0.55 (95% CI 0.36-0.84). ","cbCaipnN9iEfqsgj","https://ap.wps.com/l/cbCaipnN9iEfqsgj","pdf",2547649,"English","# Article overview\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the purpose of the GIM2 exploratory analysis?\",\"answer\":\"To investigate the efficacy of dose-dense adjuvant chemotherapy in HER2-negative breast cancer, stratified by HER2 immunohistochemistry (IHC) score categories.\"},{\"question\":\"How were tumors classified based on HER2 status in the study?\",\"answer\":\"HER2 score 0 tumors were labeled HER2-zero; tumors with HER2 score 1+ or 2+ without ISH amplification were classified as HER2-low; cases with unknown IHC score were grouped separately.\"},{\"question\":\"Did the study find that DD chemotherapy benefited patients regardless of HER2 status?\",\"answer\":\"Yes. No interaction between treatment effect and HER2 status was observed for invasive disease-free survival or overall survival, and efficacy signals were reported across HER2-zero and HER2-low groups.\"}]","Dose-dense adjuvant chemotherapy in HER2-low breast cancer - An exploratory analysis of the GIM2 trial | PDF",1790129839,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32c7d42161804a86477b2b67319bd1af.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/927dec386cf88acfddc744c8ff615e50.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e91ada58ff33cca3bdc24acd8ccdf9d.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64cfdb9c71e2a6628348df878f564100.webp",980,1306]